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Erythropoietin (EPO) possesses generalized neuroprotective and
neurotrophic actions. We tested the efficacy of recombinant hu-
man EPO (rhEPO) in preventing and reversing nerve dysfunction in
streptozotocin (STZ)-induced diabetes in rats. Two days after STZ
[60 mgkg of body weight (b.w.), i.p.], diabetic animals were
administered rhEPO (40 gkg of b.w.) three times weekly for 5
weeks either immediately (preventive) before or after a 5-week
delay (therapeutic) after induction of hyperglycemia or at a lower
dose (8 gkg of b.w. once per week) for 8 weeks (prolonged).
Tail-nerve conduction velocities (NCV) was assessed at 5 and 11
weeks for the preventive and therapeutic schedule, respectively.
Compared to nondiabetic rats, NCV was 20% lower after 5 weeks
in the STZ group, and this decrease was attenuated 50% by rhEPO.
Furthermore, the reduction of Na,K-ATPase activity of diabetic
nerves (by 55%) was limited to 24% in the rhEPO-treated group. In
the therapeutic schedule, NCV was reduced by 50% after 11 weeks
but by only 23% in the rhEPO-treated group. rhEPO treatment
attenuated the decrease in compound muscle action potential in
diabetic rats. In addition, rhEPO treatment was associated with a
preservation of footpad cutaneous innervation, as assessed by
protein gene product 9.5 immunostaining. Diabetic rats developed
alterations in mechanical and thermal nociception, which were
partially reversed by rhEPO given either in a preventative or
therapeutic manner. These observations suggest that administra-
tion of rhEPO or its analogues may be useful in the treatment of
diabetic neuropathy.
Polyneuropathy is the most common complication of diabetesmellitus, occurring in 50% of patients who have been
hyperglycemic for 15 years (1, 2). Neuropathy contributes the
greatest morbidity and mortality and severely impairs the quality
of life (3, 4) because of paresthesia, pain, and neuropathic injury,
the leading cause of nontraumatic amputation in the U.S.
Hyperglycemia is critical for the development and progression of
diabetic neuropathy (1, 2), with the two main pathogenic hy-
potheses focusing on a metabolic vs. vascular etiology. Despite
many studies of human and experimental diabetic neuropathy,
the current therapeutic arsenal is very poor.
We have previously shown that recombinant human erythro-
poietin (rhEPO) crosses the blood–brain barrier and has a
protective effect in animal models of cerebral ischemia and
traumatic injury (5). In primary neuronal cultures or neuronal
cell lines and in cerebral ischemia, rhEPO protects from apo-
ptosis (6, 7). rhEPO also reduces injury in experimental auto-
immune encephalomyelitis, injury of spinal cord, or sciatic nerve
compression (8). i.v. rhEPO is well tolerated and beneficial in
patients with acute ischemic stroke (9). Prior work has docu-
mented that, within the sciatic nerve, both neurons and Schwann
cells express the EPO receptor, which is up-regulated after injury
(10). Furthermore, a potential beneficial role for rhEPO in
mechanical peripheral nerve injury has been recently shown, for
which rhEPO treatment protects dorsal root ganglion neurons
from undergoing apoptosis (11).
The present study is aimed at investigating the efficacy of
rhEPO in preventing andor treating peripheral diabetic neu-
ropathy. To accomplish this, we studied rats with streptozotocin
(STZ)-induced diabetes, which, like human diabetic neuropathy,
have alterations in nociceptive thresholds (thermal and mechan-
ical). In this model, we evaluated thermal and mechanical
nociceptive thresholds, supplemented by nerve conduction ve-
locity (NCV) and compound muscle action potentials (CMAP),
and sciatic nerve Na,K-ATPase content.
Some authorities have considered the first fibers affected in
diabetic neuropathy to be the small sensory ones (12–14). In
addition, recent data show that the degeneration of intraepider-
mal nerve fiber (IENF), somatic unmyelinated axons, correlates
with both the presence and severity of sensory neuropathy
(15–18). We have assessed the involvement of IENF in the
STZ-diabetic rat model by quantifying density in rat footpad skin
by use of protein gene product 9.5 (PGP 9.5), a specific marker.
Administration of rhEPO in all these experiments reduces loss
of function in the diabetic state.
Methodology
Animal Experimentation. Procedures involving animals and their
care were conducted in conformity with the institutional guide-
lines in compliance with national (Law by Decree No. 116,
February 18, 1992, Gazzetta Ufficiale della Repubblica Italiana,
Suppl. 40) and international laws and policies (European Eco-
nomic Community Council Directive 86609, December 12,
1987, in Official Journal of Law, p. 358; Guide for the Care and
Use of Laboratory Animals, U.S. National Research Council,
1996). The protocols for the proposed investigation were re-
viewed and approved by the Animal Care and Use Committees
of the Istituto di Ricerche Farmacologiche ‘‘Mario Negri’’
(Milan) and the Faculty of Medicine, University of Mersin. After
an overnight fast, male Sprague–Dawley (Charles River Breed-
ing Laboratories) or Wistar rats (Selcuk University Medical
Faculty, Konya, Turkey) (200–230 and 265–280 g, respectively)
received a single injection [60 mgkg of body weight (b.w.), i.p.,
in sodium citrate buffer, pH 4.5] of STZ (Sigma–Aldrich). Only
STZ-treated rats with urine glucose levels of 15 mM 2 days
after STZ injection were included in the study. Rats were
randomized and housed two to three per cage with free access
to food and water in a 12-hour lightdark cycle. Control animals
were age-matched and given saline instead of STZ.
Experimental Design. For preventive studies, Sprague–Dawley
diabetic rats were treated with rhEPO (Dragon Pharmaceuticals,
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CMAP, compound muscle action potential; IENF, intraepidermal nerve fiber; NCV, nerve
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Vancouver) 40 gkg of b.w., i.p., three times per week for 5
weeks starting on day 2 (‘‘preventive’’ schedule), whereas Wistar
rats were treated with 8 gkg of b.w., i.p., rhEPO weekly for 4
and 8 weeks (‘‘prolonged’’ schedule). In the therapeutic sched-
ule, treatment with rhEPO was started 5 weeks after diabetes
induction and lasted an additional 5 weeks. Rats were treated
with rhEPO (40 gkg of b.w. i.p.) three times per week. The
treatment schedules are outlined in Fig. 1. Growth rate, water
and food intake, and mechanical and thermal nociceptive thresh-
olds were measured weekly. When indicated, NCV was
measured. Plasma glucose, hemoglobin concentration, and he-
matocrit were evaluated at the end of the experiments. Na,K-
ATPase activity in the sciatic nerve was assessed as described
(19). An estimate of IENF density was determined by counting
nerve fibers visualized by PGP 9.5 immunohistochemistry of the
footpad skin by a method previously described (20). Briefly,
hind-paw footpad skin was fixed in 2% paraformaldehyde-lysine-
periodate for 24 h at 4°C, cryoprotected overnight, and serially
cut with a cryostat to obtain 20-m sections. Three sections were
randomly selected and immunostained with polyclonal anti-PGP
9.5 (Biogenesis, Poole, U.K.) by using a free-floating protocol
described by McCarthy et al. (21). Three blinded observers
counted the total number of IENF in each section under a light
microscope at high magnification, with the assistance of a
microscope-mounted video camera. Individual fibers were
counted as they crossed the dermal–epidermal junction, whereas
secondary branching within the epidermis was excluded from the
quantification. The length of the epidermis was measured by
using a computerized system (Microscience, Seattle) and the
linear density of IENF obtained.
Nociceptive Thresholds. Thermal nociceptive threshold to radiant
heat was quantified by using the paw withdrawal in a hot plate
test (22). Withdrawal latency was defined as time between
placement on the hot plate and time of withdrawal and licking
of hind paw. Each animal was tested twice, separated by a 30-min
rest interval. The mechanical nociceptive threshold was quanti-
fied by using the Randal–Selitto paw withdrawal test (23) with
an analgesy meter (Ugo Basile, Comerio, Italy), which generates
a linearly increasing mechanical force. The results represent the
maximal pressure (expressed in grams) tolerated by the animals.
The thermal nociceptive threshold response utilizes a polysyn-
aptic pathway involving higher centers, whereas the mechanical
nociceptive threshold is a monosynaptic response. In agreement
with others, in these experiments, diabetes was associated with
an increase in the threshold of thermal withdrawal and a
decrease in threshold for mechanical stimulation. Rats were
accustomed to the devices 3 days before performing the tests. At
each time point, animals were tested with three trials, and the
values were averaged.
Electrophysiological Techniques. Antidromic tail-nerve conduction
velocity was assessed by using a Myto EBNeuro electromiograph
(EBNeuro, Firenze, Italy), as described (24). The latency of
potential recorded in the two sites after nerve stimulation
(stimulus duration, 100 msec; filter, 1 Hz to 5 MHz) was
determined (peak to peak), and NCV was calculated accord-
ingly. Standardized electromyography and nerve conduction
techniques were used for recording CMAP of the gastrocnemius
muscle (25). Data were collected with a MP100 acquisition
system (Biopac Systems, Santa Barbara, CA).
Results
After 5, 8, or 11 weeks, all diabetic rats remained hyperglycemic,
and rhEPO treatment did not significantly affect blood glucose
levels (not shown). Hematocrit in rhEPO-treated rats, either
control or diabetic, was significantly increased after week 5 for
both the preventive and therapeutic schedule of treatments in
diabetic animals (45% and 28% above-normal animals, respec-
tively). After 8 weeks for the prolonged preventive schedule, a
rise of 40% above normal was observed.
Effects of Diabetes and rhEPO Treatment on Mechanical and Thermal
Nociceptive Thresholds. Fig. 2A shows the hind-paw thermal- and
force-withdrawal (mechanical) thresholds, measured 5 weeks
after induction of diabetes, in the experiments when rhEPO was
given with the short preventive schedule. After STZ treatment,
the thermal response latency and force withdrawal thresholds
significantly changed from week 2 (data not shown) until week
5 (Fig. 2A). rhEPO administration did prevent (STZEPO vs.
STZ P  0.05 by Tukey–Kramer test) the increases in thermal
nociceptor latency and the decrease in mechanical thresholds in
diabetic rats (Fig. 2 A). rhEPO treatment did not change the
thermal response latencies in non-STZ-treated rats at any time
point.
In Fig. 2B, the hind-paw thermal- and force-withdrawal
thresholds in the therapeutic schedule experiment at week 9 are
presented. As in the preventive study, diabetic rats showed
thermal hypoalgesia and also a decrease in the mechanical
thresholds at 5 weeks when groups were randomized to treat-
ments in the therapeutic experiment. In this therapeutic modal-
ity, rhEPO was able to significantly ameliorate the thermal
response latency from week 7 until week 11. The force-
withdrawal threshold in diabetic rats was significantly lower (by
30–46%) at all time points than for control rats. rhEPO treat-
ment partially restored the diabetic mechanical hyperalgesia.
Effects of Diabetes and EPO Treatment on Electrophysiological Pa-
rameters. The results on tail NCV measured 5 weeks after STZ
injection showed that the observed reduction in NCV in diabetic
group (21%) was prevented by 50% by rhEPO (control,
32.7  0.52; STZ, 25.7  0.46; STZ plus EPO, 28.1  0.44;
msec, data are the mean  SEM). When rhEPO was admin-
istered according to the therapeutic schedule, the NCV reduc-
Fig. 1. Schematic representation of the treatment schedules used.
Fig. 2. rhEPO prevents and restores changes in thermal and mechanical
thresholds in diabetic rats. Control or STZ-diabetic rats were treated with
rhEPO according to the preventive (A) or therapeutic (B) schedule. Thermal
sensitivity threshold (x axis) is expressed as withdrawal latency in seconds.
Mechanical threshold (y axis) is expressed as paw withdrawal latency in grams.
Measurements were carried out at 5 (A) or 9 (B) weeks. Data are the mean 
SEM (number of rats in each group is indicated in parentheses).
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tion in diabetic group at week 11 was 42% as compared with
nondiabetic controls, and rhEPO partially counteracted this
decrease (Fig. 3). We also evaluated the CMAP in the gastroc-
nemius muscle. As shown in Fig. 4, the peak-to-peak amplitude
of sciatic nerve CMAP, which mainly reflects axonal dysfunc-
tion, was decreased by 30% in diabetes, an effect significantly
attenuated by rhEPO, administered in the prolonged preventive
schedule.
Footpad Intraepidermal Nerve Fiber Density. In diabetic rats, the
IENF density is unchanged at 5 weeks of diabetes (data not
shown), but it was significantly reduced in diabetic rats at week
11 (end of therapeutic schedule). Fig. 5 shows a representative
microphotograph of PGP 9.5 immunostaining of IENF in the
footpad of control (Fig. 5A), diabetic (Fig. 5B) and rhEPO-
treated diabetic rats (Fig. 5C). It is clearly seen that diabetic rats
have a marked decrease in cutaneous innervation density; this is
completely reversed by rhEPO administration. A quantification
of IENF density, indicating a statistically significant protective
effect of rhEPO, is shown in Fig. 5D.
Effects of Diabetes and rhEPO Treatment on Na,K-ATPase Activity.
As expected, Na,K-ATPase activity was significantly reduced
in sciatic nerve from diabetic rats. At 5 weeks (preventive
schedule), Na,K-ATPase activity was reduced (55%) by
diabetes, and this reduction was prevented by rhEPO (control,
1.44  0.23; control plus EPO, 1.48  0.14; STZ, 0.65  0.27;
STZEPO, 1.09 0.08; molmin per mg protein; data are the
mean SEM). When rhEPO was administered according to the
therapeutic schedule, the reduced Na,K-ATPase activity
(50%) was also restored (Fig. 6).
Discussion
The results of this study demonstrate an amelioration effect of
systemically administered rhEPO in a rat model of peripheral
diabetic neuropathy. In this model, rhEPO partially reversed
diabetes-induced loss in nerve functions (NCV and CMAP),
cutaneous innervation (IENF density), Na,K-ATPase activ-
ity, and impairment in nociceptive thresholds. rhEPO was ef-
fective with a preventive schedule where it was given immedi-
ately, after the induction of diabetes when the destruction of the
 cells is already permanent but before the onset of neuropathy,
and also in a therapeutic schedule, i.e., administered when
neuropathy was evident.
EPO could modulate on several of the pathogenic pathways
implicated in peripheral diabetic neuropathy. This complication
is thought to arise from biochemical changes (e.g., protein
glycation of cellular proteins, exaggerated flux through the
polyol pathway, reduced Na,K-ATPase, and neurotrophic
factors. In addition, increased oxidative stress (26) and vascular
alterations [decreased microvascular blood flow, increased vas-
cular resistance, and altered vascular permeability (27, 28)] are
believed to lead to functional (decreased nerve conduction
velocity and nerve blood flow) and structural abnormalities (29,
30). In particular, in STZ-diabetic rats, there are evidences of
apoptosis of dorsal root ganglia sensory neurons and Schwann
cells (31), possibly due to oxidative stress driven by hyperglyce-
mia (32, 33). Our prior work has shown that EPO prevents
neuronal apoptosis in vitro in hypoxic neurons and in vivo in
cerebral ischemia in rats (7). Further, a recent study has found
that rhEPO prevents apoptosis in the dorsal root ganglia in rats
subjected to a mechanical injury of the sciatic nerve (11). The
neurotrophic action of rhEPO (7) could also be important for the
effects reported in this paper.
Another pathogenic component of peripheral diabetic neu-
ropathy is inflammation, and we previously reported that ex-
perimental diabetic neuropathy is associated with endoneurial
induction of inflammatory cytokines and macrophage infiltra-
tion (34, 35). This could also be affected by rhEPO, because
rhEPO decreases brain inflammation in models of cerebral
ischemia (36) and experimental autoimmune encephalomyeli-
tis (37).
Microvascular changes in diabetes mellitus are a final common
pathway for late complications, including nerve, heart, kidney,
and eye. Studies in humans and in experimental diabetes have
shown a reduced nerve blood flow and endoneurial hypoxia in
the peripheral nerves (29), and rhEPO was reported to amelio-
rate neurovascular dysfunction in models of subarachnoid hem-
orrhage and spinal cord injury (38, 39). In the neurovascular
Fig. 3. rhEPO restores the decrease in NCV in diabetic rats. Experimental
design was the same as in Fig. 1. Tail NCV was measured at 11 weeks (thera-
peutic schedule). Data are expressed as msec and are the mean  SEM
(number of rats is indicated in parentheses). *, P  0.001 vs. nondiabetic
control by Tukey–Kramer test; †, P  0.01 vs. STZ.
Fig. 4. rhEPO prevents the decrease in CMAP in diabetic rats. CMAP was
evaluated at week 8. rhEPO was administered according to the prolonged
preventive schedule. Data are expressed as mV and are the mean  SEM
(number of rats is indicated in parentheses). *, P  0.005 vs. nondiabetic
control by Tukey–Kramer test; †, P 0. 005 vs. nondiabetic control; ‡, P 0.01
vs. diabetic groups.
Bianchi et al. PNAS  January 20, 2004  vol. 101  no. 3  825
M
ED
IC
A
L
SC
IE
N
CE
S
context, angiogenesis helps perfusion in metabolically compro-
mised tissue, and angiogenesis after rhEPO has been reported in
vitro and in vivo (40).
The beneficial efficacy of EPO on NCV and nociception was
associated with an effect on IENF density, evaluated by immu-
nohistochemistry by using an anti-PGP 9.5 antibody. PGP 9.5 is
a cytoplasmic ubiquitin C-terminal hydrolase expressed in all
types of efferent and afferent peripheral nerve fibers. Skin
biopsies obtained from patients with diabetes mellitus show
uniform reduction in the content of PGP 9.5 (41, 42). Quanti-
fication of epidermal axon number in skin biopsies confirmed
the loss of cutaneous nerve fibers in diabetic subjects with
symptoms of neuropathy, and this reduction correlates with
electrophysiological and somatosensory deficits (18, 43, 44).
Consistent with these observations, we observed a severe reduc-
tion in cutaneous innervation of footpad skin of STZ-diabetic
rats. Our results are in agreement with recent findings in
genetically diabetic C57BLKs J-MLeprdb (dbdb) mice
and STZ-diabetic mice in which cutaneous innervation is sig-
nificantly reduced (17, 45). The protective effect of rhEPO on
the decrease in IENF density could explain the observed pro-
tection from impairment of thermal and, to a lesser extent,
mechanical sensitivities. Moreover, the finding that rhEPO
prevents the decrease in CMAP in diabetic rats suggests that
rhEPO also prevents the loss of functional nerve fibers in the
gastrocnemus or improves their functionality.
Some neurotrophic factors (like NGF) prevent thermal hy-
poalgesia by beneficial effects on small-diameter fibers, whereas
others (like neurotrophin-3) selectively protect large sensory
neurons (46–49). The development of thermal hypoalgesia in
STZ-diabetic rats was partially prevented and restored by
rhEPO, which had no effect in nondiabetic animals. Thus,
beneficial rhEPO effects appear to be selectively directed to
abnormal nociception in diabetes without effects on normal
thermal nociception. These results are in agreement with action
of some neurotrophic factors but differ from others, like NGF,
which, while attenuating thermal hypoalgesia in diabetic rats,
also reduced nociceptive threshold in controls (50, 51).
Despite the complexity of nociceptive responses in diabetic
neuropathy (52), our data confirm previous results showing that
STZ diabetes in rats is associated with mechanical hyperalgesia
(53, 54). It seems that, in contrast to thermal nociception,
Fig. 5. rhEPO restores the loss of intraepidermal fibers in diabetic rats. Hind-paw skin biopsy in control (A), STZ-diabetic at 5 weeks (B), and after 5 weeks of
rhEPO treatment initiated after 5 weeks of diabetes (C). Microphotographs are PGP 9.5 immunostaining in 20-m-thick sections. (Bar  30 m.) Small arrows
indicate IENF, and large arrows indicate dermal nerve bundles. Note the fragmented and discontinuous PGP 9.5 immunoreactivity in IENF indicative of axonal
degeneration. (D) Quantification of IENF density. Data are expressed as the number of linear density of IENF and are the mean SEM (number of rats is indicated
in parentheses). *, P  0.05 vs. nondiabetic control by Tukey–Kramer test; †, P  0. 05 vs. untreated diabetic rats.
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substance P is not involved in mechanical hyperalgesia, where
GABA and opiates seem to play a major role (54). These
differences in the neuromediators involved, as well as spinal vs.
supraspinal sensory processing, might explain the differential
effect of rhEPO on the different nociceptive thresholds.
At the biochemical level, potential etiologic mechanisms to
explain the slowing of NCV during hyperglycemia include de-
creased activity of Na,K-ATPase in peripheral nerves and
atrophy of large myelinated fibers (30). We previously observed
that the Na,K-ATPase in the peripheral nerves is sensitive to
environmental hypoxic conditions (55). It is important to note
that our previous work has shown that, in diabetic patients, both
the total number of fibers and the specific activity of Na,K-
ATPase are decreased (56), indicating that diabetic neuropathy
is not only due to a loss in nerve fibers but also to a decrease in
their functionality. We report here that rhEPO prevents and
restores the loss of Na,K-ATPase activity in diabetic rats,
suggesting that rhEPO might also ameliorate the functionality of
existing fibers, in agreement with the neurotrophic effect of
rhEPO reported in different experimental models (7, 57).
A number of agents have been previously shown to have
activity preventing the onset of diabetic neuropathy (29). A few
have been shown to have some reversing activity. N-acetylcys-
teine, a hydrophilic antioxidant and sulfydryl donor, has been
shown to reverse NCV and nerve blood flow after 1 month of
untreated diabetes and improved sciatic nerve mylenated fiber
regeneration (58). A neurotrophic peptide of prosaposin proved
efficacious in preventing onset of large and small fiber dysfunc-
tion and thermal hypoalgesia in diabetic rats (50). Tumor
necrosis factor  (TNF-) acutely induces hyperalgesia, and
prosaposin-derived peptide counteracts this activity (59). By
additionally reducing TNF production, prevention and reversal,
along with almost complete normalization of sciatic nerve
myelinated fibers, has been reported (60). In one successful
experiment using a probucol derivative, coadministration of a
NO synthase inhibitor abolishes the effects of antioxidants,
suggesting that the benefits arise from effects on the neurovas-
culum (61). Finally, lipoic acid has been shown in diabetic
patients to improve function and reduce symptoms in patients
with established diabetic polyneuropathy (62).
These observations strongly suggest that administration of
rhEPO may be useful in the treatment of diabetic neuropathy.
However, although in acute brain injury such as cerebral isch-
emia or brain trauma, a single injection of rhEPO was sufficient
to obtain a protective effect (5), in the present study, rhEPO was
administered over a long period (5–8 weeks). With this schedule,
a marked increase in the hematocrit was observed. This could
represent a potentially serious side effect and increase the risk
of cerebrovascular accidents. Therefore, in the setting of chronic
diseases, it will be important to develop nonerythropoietic
analogues of EPO. Significant progress has been made toward
this goal: we recently have reported on the efficacy of asialo-
erythropoietin, an analogue with a markedly reduced half life
(8). Although experiments have shown that asialoEPO protects
from sciatic nerve compression, further testing will be required
to determine whether asialoEPO is also active in diabetic
neuropathy.
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